<DOC>
	<DOCNO>NCT02529241</DOCNO>
	<brief_summary>To investigate pharmacokinetics , safety tolerability LCB01-0371 , LCB01-0371-B single oral dose healthy male subject . To investigate safety , tolerability LCB01-0371 single oral dose healthy male subject .</brief_summary>
	<brief_title>An Open-label , Single Dose , Parallel Design , Phase 1 Clinical Study LCB01-0371</brief_title>
	<detailed_description>An Open-label , Single dose , Parallel design , Phase I Study Investigate Pharmacokinetics , Safety , Tolerability Oral dosage form LCB01-0371 Healthy Male Volunteers</detailed_description>
	<criteria>1 . Healthy male 20 40 year age time screen 2 . Agree continue use medically reliable dual contraception donate sperm protocol duration study 28 day last dose investigational product 3 . Capable give write informed consent , willing participate clinical trial , willing comply study requirement 1 . History gastrointestinal problem ( e.g . Crohn 's disease , gastrointestinal ulcer ) within 6 month possibly affect absorption clinical trial drug , history surgery ( except simple appendectomy herniotomy ) 2 . History hypersensitivity reaction history clinically significant hypersensitivity reaction LCB010371 class study drug ( linezolid ) drug include aspirin antibiotic 3 . History clinically significant disease allergic anaphylactic reaction drug , cardiovascular , peripheral vascular system , skin , mucous membrane , eye , otorhinolaryngologic system , respiratory , musculoskeletal , infection disease , Gastrointestinal system , liver , biliary system , endocrine , kidney , urogenital system , nervous system , psychiatric system , blood dyscrasia , tumor , fracture , problem ( ) 4. blood donation transfusion within 60 day prior screen visit 5 . Treatment investigational product Participation bioequivalence test within 90 day prior screen visit 6 . Use medication expect influence study within 30 day prior screen visit 7. smoker 10 cigarette per day within 30 day prior screen visit unable stop smoking protocol duration study first dose investigational product 8. drinker 3 glass alcohol drink per week within 30 day prior screen visit unable stop drinking protocol duration study first dose investigational product 9. positive result urine drug screen test urine nicotine test screen visit 10. positive result serum test ( hepatitis B , hepatitis C , HIV , syphilis ) screen visit 11. correct QT interval &gt; 450 msec significant abnormality screen ECG 12. : Patients consider unable perform study investigator concern</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>